Constantijn Franssen

ORCID: 0000-0002-7085-5317
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiovascular Function and Risk Factors
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Cardiomyopathy and Myosin Studies
  • Cardiac pacing and defibrillation studies
  • Heart Failure Treatment and Management
  • Cardiac Structural Anomalies and Repair
  • Pregnancy and preeclampsia studies
  • Cardiac Imaging and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cardiac electrophysiology and arrhythmias
  • Cancer Treatment and Pharmacology
  • Cardiovascular Issues in Pregnancy
  • Nitric Oxide and Endothelin Effects
  • Birth, Development, and Health
  • Congenital Heart Disease Studies
  • Receptor Mechanisms and Signaling
  • Electron Spin Resonance Studies
  • Takotsubo Cardiomyopathy and Associated Phenomena
  • Primate Behavior and Ecology
  • Cardiac tumors and thrombi
  • Adenosine and Purinergic Signaling
  • Neurosurgical Procedures and Complications
  • Cardiac Ischemia and Reperfusion
  • Ferroptosis and cancer prognosis
  • Childhood Cancer Survivors' Quality of Life

Antwerp University Hospital
2016-2025

University of Antwerp
2018-2025

Amsterdam UMC Location VUmc
2011-2018

University Medical Center
2017-2018

University Hospital and Clinics
2018

Ruhr University Bochum
2013-2017

Longwood University
2016

Universidade do Porto
2013

Universidad de Navarra
2013

Background— Obesity and diabetes mellitus are important metabolic risk factors frequent comorbidities in heart failure with preserved ejection fraction. They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification. The relative importance for DD of modification was investigated obese, diabetic ZSF1 rats after fraction development at 20 weeks. Methods Results— Four groups (Wistar-Kyoto, n=11; lean ZSF1, obese n=11, high-fat diet, n=11) were...

10.1161/circheartfailure.113.000539 article EN Circulation Heart Failure 2013-09-07

Apart from cardiotoxicity, the chemotherapeutic doxorubicin (DOX) induces vascular toxicity, represented by arterial stiffness and endothelial dysfunction. Both parameters are of interest for cardiovascular risk stratification as they independent predictors future events in general population. However, time course DOX-induced toxicity remains unclear. Moreover, current biomarkers prove insufficient. Here, we longitudinally evaluated functional molecular markers a murine model. Molecular were...

10.1093/cvr/cvad136 article EN cc-by-nc Cardiovascular Research 2023-08-23

Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial early diagnosis and therapy guidance. Currently, relies on cardiac imaging serial measurement of biomarkers like troponin natriuretic peptides. However, these conventional are nonspecific indicators damage. Exploring new, more specific with a clear link to the underlying pathomechanism holds promise increased specificity sensitivity in detecting anthracycline-induced cardiotoxicity. miRNAs (microRNAs), small...

10.1016/j.jaccao.2023.12.009 article EN cc-by-nc-nd JACC CardioOncology 2024-02-27

Abstract Background The anthracycline doxorubicin (DOX) is a highly effective anticancer agent, especially in breast cancer and lymphoma. However, DOX can cause therapy-related cardiovascular toxicity (CTR-CVT) patients during treatment survivors. Current diagnostic criteria for CTR-CVT focus mainly on left ventricular systolic dysfunction, but certain level of damage required before it be detected. As diastolic dysfunction often precedes the current study aimed to identify functional...

10.1186/s40959-024-00241-1 article EN cc-by Cardio-Oncology 2024-06-22

Abstract Background Disseminated Aspergillus infection is a severe condition in immunocompromised patients. Mortality secondary to cardiac remains high. Case summary We present case of 45-year-old female breast cancer patient who developed fumigatus endocarditis and myocarditis after receiving the immune checkpoint inhibitor (ICI) pembrolizumab. The emerged as complication following management immune-related adverse event (irAE) with high doses immunosuppressants, triggered by ICI....

10.1093/ehjcr/ytaf058 article EN cc-by-nc European Heart Journal - Case Reports 2025-02-04

Tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) receptor signalling are used in cancer therapy to inhibit angiogenesis. Unfortunately, VEGF known induce severe hypertension patients. This study aimed elucidate the impact of TKI lenvatinib on blood pressure, arterial stiffness, reactivity, as well cardiac function a short-term murine model shed light potential contributors cardiovascular (CV) toxicities associated with inhibition. Male C57BL/6J mice were...

10.1186/s40959-025-00307-8 article EN cc-by-nc-nd Cardio-Oncology 2025-02-11

Abstract Background SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with therapy-related cardiac dysfunction (CTRCD) circulating was elevated compared to age-matched controls. We aimed assess the longitudinal dynamics levels patients treated anthracycline chemotherapy (AnC) and its relation CTRCD. Methods this single centre cohort study, 55 scheduled for AnC were prospectively enrolled. Cardiac evaluation (echocardiography,...

10.1186/s40959-025-00324-7 article EN cc-by Cardio-Oncology 2025-03-14

Background Systemic inflammation, endothelial dysfunction and deficient vascularization of either uterus or myocardium are mechanistic hallmarks early-onset preeclampsia heart failure with preserved ejection fraction (HFpEF). HFpEF is especially prevalent in elderly women preceded middle age by preclinical left ventricular (LV) diastolic dysfunction. To detect if predisposes to at later age, echocardiographic indices LV function structure biomarkers systemic inflammation were compared...

10.1371/journal.pone.0198908 article EN cc-by PLoS ONE 2018-06-12

Abstract Background Variants in cardiomyopathy genes have been identified patients with cancer therapy-related cardiac dysfunction (CTRCD), suggesting a genetic predisposition for the development of CTRCD. The diagnostic yield testing CTRCD population compared to patient cohort is not yet known and information on which should be assessed this lacking. Methods We retrospectively included 46 history anthracycline induced (defined as decrease left ventricular ejection fraction (LVEF) < 50% ≥...

10.1186/s40959-024-00231-3 article EN cc-by Cardio-Oncology 2024-04-30

Enriched environments are beneficial to neurobiological development; specifically, rodents exposed complex, rather than standard laboratory, exhibit evidence of neuroplasticity and enhanced cognitive performance. In the present study, nature elements placed in complex environment was investigated. Accordingly, rats (n = 8 per group) were housed either a natural characterised by stimuli such as dirt rocks, an artificial plastic toys synthetic nesting materials, natural/artificial combination...

10.1111/jne.12383 article EN Journal of Neuroendocrinology 2016-03-13

Doxorubicin (dox) is an affordable, and highly effective chemotherapeutic agent used in cancer treatment, yet its application known to cause cumulative cardiac renal toxicity. In this study, we employed matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) evaluate the distribution of dox mouse heart kidney after vivo treatment. To end, performed absolute quantification using isotopically labeled form (13C d3-dox) as internal standard. Unfortunately, ion...

10.1016/j.talanta.2024.125667 article EN cc-by Talanta 2024-01-19

Cardiomyocytes with a less distensible titin and interstitial collagen contribute to the high diastolic stiffness of failing myocardium. Their relative contributions mechanisms underlying loss distensibility were assessed in human hearts.Left ventricular tissue was procured patients aortic stenosis (AS, n=9) dilated cardiomyopathy (DCM, n=6). Explanted donor hearts (n=8) served as controls. Stretches performed myocardial strips, an extraction protocol differentiated between passive tension...

10.1161/circheartfailure.116.003626 article EN Circulation Heart Failure 2017-02-28

Apart from cardiotoxicity, the chemotherapeutic agent doxorubicin (DOX) provokes acute and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of DOX-induced yet it remains currently unknown whether DEXRA prevents toxicity associated with DOX. Accordingly, present study aimed to evaluate protective potential against DOX-related in a previously-established vivo ex model dysfunction induced by 16 hour (h) DOX exposure. Vascular function was evaluated thoracic...

10.1371/journal.pone.0294848 article EN cc-by PLoS ONE 2023-11-28
Coming Soon ...